MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

ENSC — Ensysce Biosciences, Inc. Common Stock

Nasdaq

Ensysce Biosciences, Inc. Common Stock

CompareBack to Screener
$0.40
-0.00(-1.20%)
O
0.41
H
0.43
L
0.39
V
173.06K
⏱️ End-of-day dataAs of Oct 2, 2026

Chart

About ENSC

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJul 1, 2021
Employees10
Stock ExchangeNasdaq
Ticker SymbolENSC

Key Financial Statistics

Market Cap$7.69M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$0.23 - $2.75
52-Week Avg Volume5.21M
VWAP$0.40
Transactions702
Total Recorded Bars2,151 days